- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Alpha Teknova (TKNO) Stock Moves Higher on Booming Clinical Demand | 3 | Insider Monkey | ||
| Do | Teknova targets less than $8M 2026 free cash outflow as it lifts revenue guide to $45M-$47M | 1 | Seeking Alpha | ||
| Do | Teknova Q2 2026 slides: record revenue, raised guidance, EBITDA target | 1 | Investing.com | ||
| Do | Teknova Q2 2026 slides: record revenue, AI tool, profitability path | 1 | Investing.com | ||
| Mi | Alpha Teknova GAAP EPS of -$0.06 beats by $0.03, revenue of $12.2M beats by $1.29M | 1 | Seeking Alpha | ||
| Mi | Alpha Teknova, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| Mi | Alpha Teknova, Inc.: Teknova Launches Build-Tek, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes | 1 | GlobeNewswire (USA) | ||
| ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
| Mi | Roth/MKM stuft Alpha Teknova Aktie mit "Buy" ein und sieht deutliches Wachstumspotenzial | 1 | Investing.com Deutsch | ||
| Mi | Roth/MKM initiates Alpha Teknova stock with buy rating on growth outlook | 1 | Investing.com | ||
| 22.07. | Alpha Teknova, Inc.: Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026 | 2 | GlobeNewswire (USA) | ||
| 16.06. | Bioz, Inc.: Teknova Expands Digital Publication Experience with Bioz Content Hub Integration | 339 | ACCESS Newswire | PALO ALTO, CA / ACCESS Newswire / June 16, 2026 / Bioz, Inc., an innovative platform focused on extracting and syndicating insights from scientific publications, announced its continued collaboration... ► Artikel lesen | |
| 01.06. | Alpha Teknova, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Alpha Teknova GAAP EPS of -$0.08 beats by $0.01, revenue of $11.07M beats by $0.85M | 1 | Seeking Alpha | ||
| 07.05. | Alpha Teknova Q1 2026 slides: 13% revenue growth, margins expand | 1 | Investing.com | ||
| 06.05. | Alpha Teknova, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | Alpha Teknova, Inc.: Teknova to Report First Quarter 2026 Financial Results on May 6, 2026 | 1 | GlobeNewswire (USA) | ||
| 19.03. | Alpha Teknova stellt Wachstumsplan vor: EBITDA-Profitabilität bis 2027 angestrebt | 2 | Investing.com Deutsch | ||
| 02.03. | Alpha Teknova, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.02. | Alpha Teknova, Inc. Q4 Loss Decreases | - | RTTNews |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,490 | -2,73 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,207 | +5,08 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,172 | +0,79 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| ARROWHEAD PHARMACEUTICALS | 74,84 | -1,29 % | Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events | ||
| ARBUTUS BIOPHARMA | 3,980 | -0,50 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Laufende Fusionskontrollverfahren: Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USA | Datum der Anmeldung:23.07.2026Aktenzeichen:B3-85/26Unternehmen:Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ALDEYRA | 1,350 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| ABCELLERA BIOLOGICS | 5,950 | -0,67 % | AbCellera rises as it will release phase 2 results of menopause asset | ||
| ADAPTIVE BIOTECHNOLOGIES | 21,370 | -0,84 % | Adaptive Biotechnologies Corp - 10-Q, Quarterly Report | ||
| BIOMERIEUX | 73,05 | 0,00 % | BioMerieux H1 Net Sales Slip On Foreign Exchange Impact; Backs Annual Sales Growth Outlook | PARIS (dpa-AFX) - BioMérieux SA (EYWN.MU, BIM.PA), a French biotechnology company, on Tuesday reported an increase in net income for the first half of fiscal 2026, helped by a drop in amortization... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| AC IMMUNE | 2,020 | -0,98 % | AC Immune SA: AC Immune First Half 2026 Financial and Corporate Update | AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances... ► Artikel lesen | |
| 10X GENOMICS | 44,700 | -0,80 % | 10x Genomics, Inc.: 10x Genomics Reports Second Quarter 2026 Financial Results | PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,780 | -1,02 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| AGIOS | 27,800 | 0,00 % | Agios Pharmaceuticals, Inc.: Agios Reports Second Quarter 2026 Financial Results and Provides Business Update | Mitapivat (PYRUKYND and AQVESME) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025Strong U.S. commercial launch... ► Artikel lesen |
Das Unternehmen ALPHA TEKNOVA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,470 Euro und damit +0,15 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TEKNOVA INC finden Sie auf Wallstreet Online.